Tier 3 — preclinical

The effects of apigenin on immune responses and inflammatory biomarkers in sepsis: a comprehensive systematic review

Ghaleb Oriquat, Waleed K Abdulsahib, Sanan Thaer Abdal-Wahab, H Malathi, Biswaranjan Mohanty, J Bethanney Janney, Vimal Arora, Aashna Sinha, Zafar Aminov
Biomarkers 2026 31(3):234-246

Bibliography

PubMed
PMID 41803677
DOI
10.1080/1354750X.2026.2641063

Study snapshot

DesignSystematic review of preclinical studies
Model30 in vitro and in vivo apigenin studies related to sepsis
Sample30 included studies
InterventionApigenin across experimental sepsis and inflammatory models
Duration
EndpointsInflammatory biomarkers; Immune responses; Organ injury; NF-κB-related signaling; PPARγ/miR-21; KEAP1/Nrf2

What the study showed, in plain terms

This 2026 systematic review summarizes experimental evidence for apigenin across sepsis-related inflammation and organ injury.

Key findings

The included preclinical studies repeatedly implicated inflammatory and oxidative-stress pathways and reported protective signals across lung, intestinal, cardiac and kidney models.

What this study can and cannot tell us

The review found no clinical trials. It cannot establish that apigenin prevents or treats sepsis in humans.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology